These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 19670957)

  • 21. Medicare Part D turns four: trends in plan design, enrollment, and the impact of the program on beneficiaries.
    Hoadley J; Simon K
    Adv Health Econ Health Serv Res; 2010; 22():123-47. PubMed ID: 20575231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry.
    Padula WV; Ballreich J; Anderson GF
    Appl Health Econ Health Policy; 2018 Dec; 16(6):753-763. PubMed ID: 30058011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
    Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
    Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis.
    Li DG; Najafzadeh M; Kesselheim AS; Mostaghimi A
    BMJ; 2019 Jul; 366():l4257. PubMed ID: 31315833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
    Sheingold S; Nguyen NX
    Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.
    Dusetzina SB; Conti RM; Yu NL; Bach PB
    JAMA Intern Med; 2017 Aug; 177(8):1185-1188. PubMed ID: 28558108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Part D coverage gap reform: trends in drug use and expenditures.
    Park J; Look KA
    Am J Manag Care; 2020 Aug; 26(8):349-356. PubMed ID: 32835462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Closing the Medicare Doughnut Hole: Changes in Prescription Drug Utilization and Out-of-Pocket Spending Among Medicare Beneficiaries With Part D Coverage After the Affordable Care Act.
    Bonakdar Tehrani A; Cunningham PJ
    Med Care; 2017 Jan; 55(1):43-49. PubMed ID: 27547949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of Medicare part D on income-related inequality in pharmaceutical expenditure.
    Carvalho N; Petrie D; Chen L; Salomon JA; Clarke P
    Int J Equity Health; 2019 Apr; 18(1):57. PubMed ID: 30992000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.
    Dusetzina SB; Keating NL
    J Clin Oncol; 2016 Feb; 34(4):375-80. PubMed ID: 26644524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of an open enrollment service on costs for Medicare Part D beneficiaries.
    Leonard CE; Cohenour FV; DeLoach LA; Galdo JA
    J Am Pharm Assoc (2003); 2017; 57(3S):S225-S228. PubMed ID: 28412055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D.
    Hartung DM; Johnston KA; Irwin A; Markwardt S; Bourdette DN
    Health Aff (Millwood); 2019 Feb; 38(2):303-312. PubMed ID: 30715973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
    Patel UD; Davis MM
    J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescription drug spending and hospital use among Medicare beneficiaries with heart failure.
    McGee BT; Higgins MK; Phillips V; Butler J
    Res Social Adm Pharm; 2020 Oct; 16(10):1452-1458. PubMed ID: 31953113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost minimization of medicare part D prescription drug plan expenditures.
    Patel RA; Lipton HL; Cutler TW; Smith AR; Tsunoda SM; Stebbins MR
    Am J Manag Care; 2009 Aug; 15(8):545-53. PubMed ID: 19670958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medicare's Variation in Out-of-Pocket Costs for Prescriptions: The Irrational Examples of In-Hospital Observation and Home Infusion.
    Wright B; Dusetzina SB; Upchurch G
    J Am Geriatr Soc; 2018 Dec; 66(12):2249-2253. PubMed ID: 30264858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
    Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
    Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug benefit changes under Medicare Advantage Part D: heterogeneous effects on pharmaceutical use and expenditures.
    Ettner SL; Steers WN; Turk N; Quiter ES; Mangione CM
    J Gen Intern Med; 2011 Oct; 26(10):1195-200. PubMed ID: 21710313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medication Access in America and Medicare Part D: Prescription Shopping Saves but May Be Costly.
    Upchurch G; Disco ME; Visco JL; Huffman KF
    J Am Geriatr Soc; 2018 Jan; 66(1):33-40. PubMed ID: 29124745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019.
    Erath A; Dusetzina SB
    JAMA Netw Open; 2020 Apr; 3(4):e203969. PubMed ID: 32338754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.